Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
Elke Jäger,Mark Ringhoffer,Hans Peter Dienes,Michael Arand,Julia Karbach,Dirk Jäger,Christiane Ilsemann,Manfred Hagedorn,Franz Oesch,Alexander Knuth +9 more
323
TL;DR: It is concluded that systemic GM‐CSF enhances immune responses to melanoma‐associated peptides and supports CTL‐mediated tumor rejection in vivo.
read more
Abstract: Peptide epitopes derived from differentiation antigens of the melanocyte lineage were recently identified in human melanomas as targets for MHC-restricted cytotoxic T lymphocytes (CTL). The characterization of multiple CTL-defined antigenic determinants has opened possibilities of development of antigen-targeted vaccines. In the present study, we determined CTL reactivity against melanoma-associated peptides derived from Melan A/MART-1, tyrosinase, and gp100/Pmel17 in 3 HLA-A2+ melanoma patients. Then, we assessed the immune responses to synthetic melanoma-associated peptides injected intradermally. After 3 cycles of immunization with peptide alone, we used systemic GM-CSF as an adjuvant during the fourth cycle of immunization. Enhanced DTH reactions and CD8+ CTL responses were observed after treatment with systemic GM-CSF. Immunohistochemical characterization of DTH-constituting elements revealed infiltrates of CD4+ and CD8+ T lymphocytes and strong expression of IL-2 and gammaIFN, suggesting the activation of CD4+ ThI and CD8+ CTL by peptides presented by MHC-class-I molecules of dermal APC. Objective tumor regression was documented in all patients. We conclude that systemic GM-CSF enhances immune responses to melanoma-associated peptides and supports CTL-mediated tumor rejection in vivo.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model
Sachin Gupta,James M. Termini,Yaelis Rivas,Miguel Otero,Francesca N. Raffa,Vikas Bhat,Amjad Farooq,Geoffrey W. Stone +7 more
TL;DR: Data support a model where DNA vaccination with SPD-gp100-CD40L targets gp100 to DC in situ, induces activation of these DC, and generates a protective anti-tumor response when given in combination with IL-12p70 and GM-CSF plasmids.
Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination.
TL;DR: Recent progress in the ability to quantitatively and qualitatively monitor tumor antigen specific CD8 T-cell responses will greatly help in making rapid progress in this field.
•Journal Article
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma.
Jonathan Cebon,Elke Jäger,Mark Shackleton,Peter Gibbs,Ian D. Davis,Wendie Hopkins,Sharen Gibbs,Qiyuan Chen,Julia Karbach,Heather Jackson,Duncan MacGregor,Sue Sturrock,Hilary A. Vaughan,Eugene Maraskovsky,Antje Neumann,Eric W. Hoffman,Mathew L Sherman,Alexander Knuth +17 more
TL;DR: Clinical and immunological activity has been observed in this study where peptides were administered either with or without low dose IL-12, and no clear dose-dependent effect of rhIL-12 could be determined.
FLT3 ligand gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens.
Giulio C. Spagnoli,Judith Kloth,Luigi Terracciano,Markus Trutmann,Elena Chklovskaia,Eugenia Remmel,Christoph Noppen,Paul Zajac,Thomas Kocher,Michael Heberer +9 more
TL;DR: Investigating FLT3 ligand (FL) gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens found 6 out of 6 established tumor lines were found to express to variable extents FL gene.
•Dissertation
Ms-275 (entinostat) promotes sustained tumor regression in the context of boosting oncolytic immunotherapy
Andrew Nguyen
- 01 Oct 2013
TL;DR: Combined therapy with HDACi with oncolytic immunotherapy mediates a synergized immune attack against the tumor through subversion of immunomodulatory and CD4 depletion in the absence of MS-275 resulted in sustained tumor regression, implying that immunoregulatory cells such as CD4+ Treg play a prominent role in sustaining tumor regression.
References
Tolerance, danger, and the extended family.
TL;DR: The possibility that the immune system does not care about self and non-self, that its primary driving force is the need to detect and protect against danger, and that it does not do the job alone, but receives positive and negative communications from an extended network of other bodily tissues is discussed.
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
P. van der Bruggen,Catia Traversari,Patrick Chomez,Christophe Lurquin,E De Plaen,B Van den Eynde,Alexander Knuth,Thierry Boon +7 more
TL;DR: In this paper, a gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line, which belongs to a family of at least three genes.
3.7K
Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity
Glenn Dranoff,Elizabeth M. Jaffee,Audrey J. Lazenby,Paul Golumbek,Hyam I. Levitsky,Katja Brose,Valerie Jackson,Hirofumi Hamada,Drew M. Pardoll,Richard C. Mulligan +9 more
TL;DR: The results have important implications for the clinical use of genetically modified tumor cells as therapeutic cancer vaccines and the levels of anti-tumor immunity reported previously in cytokine gene transfer studies involving live, transduced cells could be achieved through the use of irradiated cells alone.
3K
GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
TL;DR: It is demonstrated that cooperation between GM-CSF and tumour necrosis factor-α (TNF-α) is crucial for the generation of human dendritic/Langerhans cells from CD34+ haematopoietic progenitors.
1.6K
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
Thomas Wölfel,M. Hauer,Jörg Schneider,Manuel Serrano,Catherine Wölfel,E Klehmann-Hieb,E De Plaen,Thomas Hankeln,K H Meyer zum Büschenfelde,D Beach +9 more
TL;DR: Results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a.
1.2K